| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | trifluridine/tipiracil (Lonsurf®) |
| Formulation | 15 mg/6.14 mg film-coated tablet, 20 mg/8.19 mg film-coated tablet |
| Reference number | 2764 |
| Indication | Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti‑EGFR agents |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/03/2016 |
| NICE guidance | TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |